Eligibility for Alirocumab or Evolocumab Treatment in 1090 Hypercholesterolemic Patients Referred to a Regional Cholesterol Treatment Center With LDL Cholesterol ≥70 Mg/Dl Despite Maximal Tolerated Cholesterol Lowering Therapy